Advertisement


Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

2024 ASCO Annual Meeting

Advertisement

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study that I'm presenting is a multicenter consortium study. It consists of 1,327 patients that we looked at both genomic data through the liquid biopsy Guardant360 and clinical data that we got manually from the electronic medical record system. We decided to use this large multi-consortium database to ask questions about targeted treatment use in Black versus White patients. So we found that Black and White patients had equal incidence of PIK3CA mutations. But despite this equal incidence, they had differences in targeted treatment use. Black patients ended up having significantly less targeted treatment use than White patients in this dataset. Specifically, this was for these PI3 kinase inhibitor use. When we looked at mTOR inhibitor use and CDK4/6 inhibitor use, which does not require a specific finding in ctDNA or liquid biopsy, we actually didn't find any differences. So the only targeted treatment use differences was when there was a specific targeted finding in the ctDNA profiling. The other thing we looked at after that was we looked at overall survival in this cohort. We'd previously reported overall survival in the overall 1,327 patients, and then we looked specifically at HR-positive HER2-negative metastatic breast cancer patients, and we looked at ER positive, PR negative HER2 negative, and ER positive, PR positive HER2 negative. The PR-negative patients did significantly worse in terms of overall survival and Black patients with ER positive, PR negative HER2 negative did significantly worse than White patients with the same profile. Finally, we looked at clinical trial enrollment, so we looked at whether the patients with this PIK3CA mutation with metastatic breast cancer were enrolled in clinical trials at the same rate between Black and White patients. So we found that Black patients were significantly less likely to be enrolled in a clinical trial than White patients.

Related Videos

Breast Cancer

Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease

Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with hormone receptor–positive/HER2-negative early breast cancer at increased risk of recurrence, including patients with node-negative disease, and showed a benefit in invasive disease–free survival (Abstract 512).

Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.

 

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Leukemia

Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).

Gynecologic Cancers

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).

Advertisement

Advertisement




Advertisement